ALISO VIEJO, Calif., March 25, 2019 /PRNewswire-PRWeb/ -- Ambry Genetics, a Konica Minolta Company (Ambry), and
Approximately 10 to 15% of ovarian cancer diagnoses are based on hereditary mutations of BRCA, meaning they are directly linked to mutations in the BRCA1 or BRCA2 genes passed on from a parent. Ambry's genetic tests can identify mutations in these two genes, as well as related genes involved in the DNA repair pathway, thus enabling identification of potential risk, earlier diagnosis and more precise treatment.
"We are very excited to be working with the Clovis team, which is aligned with our precision medicine initiatives," said Brigette Tippin Davis, Ph.D., FACMG, Senior Vice President of Research & Development of Ambry Genetics, Inc. "Our mission is to help identify patients eligible for optimal therapies to improve outcomes and enhance quality of life."
Clovis chose to perform retrospective BRCA testing with Ambry Genetics, a high-quality genetics lab positioned to become a key player in the precision medicine space.
About Ambry Genetics Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. Founded in 1999, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit ambrygen.com.
Press Contact: Jackie Copp press(at)ambrygen(dot)com 480-606-8180
SOURCE Ambry Genetics
Subscribe to our Free Newsletters!